SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Tsolaki Tagarak F)
 

Search: WFRF:(Tsolaki Tagarak F) > Blood Pressure Lowe...

  • de Heus, R. A. A. (author)

Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension

  • Article/chapterEnglish2019

Publisher, publication year, extent ...

  • Ovid Technologies (Wolters Kluwer Health),2019

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/284857
  • https://gup.ub.gu.se/publication/284857URI
  • https://doi.org/10.1161/jaha.119.011938DOI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background-Hypertension is common among patients with Alzheimer disease. Because this group has been excluded from hypertension trials, evidence regarding safety of treatment is lacking. This secondary analysis of a randomized controlled trial assessed whether antihypertensive treatment increases the prevalence of orthostatic hypotension (OH) in patients with Alzheimer disease. Methods and Results-Four hundred seventy-seven patients with mild-to-moderate Alzheimer disease were randomized to the calcium-channel blocker nilvadipine 8 mg/day or placebo for 78 weeks. Presence of OH (blood pressure drop >= 20/>= 10 mm Hg after 1 minute of standing) and OH-related adverse events (dizziness, syncope, falls, and fractures) was determined at 7 follow-up visits. Mean age of the study population was 72.2 +/- 8.2 years and mean Mini-Mental State Examination score was 20.4 +/- 3.8. Baseline blood pressure was 137.8 +/- 14.0/77.0 +/- 8.6 mm Hg. Grade I hypertension was present in 53.4% (n=255). After 13 weeks, blood pressure had fallen by -7.8/-3.9 mm Hg for nilvadipine and by -0.4/-0.8 mm Hg for placebo (P<0.001). Across the 78-week intervention period, there was no difference between groups in the proportion of patients with OH at a study visit (odds ratio [95% CI] 1.1 [0.8-1.5], P 0.62), nor in the proportion of visits where a patient met criteria for OH, corrected for number of visits (7.7 +/- 13.8% versus 7.3 +/- 11.6%). OH-related adverse events were not more often reported in the intervention group compared with placebo. Results were similar for those with baseline hypertension. Conclusions-This study suggests that initiation of a low dose of antihypertensive treatment does not significantly increase the risk of OH in patients with mild-to-moderate Alzheimer disease.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Donders, R. (author)
  • Santoso, A. M. M. (author)
  • Rikkert, Mgmo (author)
  • Lawlor, B. A. (author)
  • Claassen, Jahr (author)
  • Segurado, R. (author)
  • Kennelly, S. (author)
  • Howard, R. (author)
  • Pasquier, F. (author)
  • Börjesson-Hanson, Anne,1959Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry(Swepub:gu)xborja (author)
  • Tsolaki, M. (author)
  • Lucca, U. (author)
  • Molloy, D. W. (author)
  • Coen, R. (author)
  • Riepe, M. W. (author)
  • Kalman, J. (author)
  • Kenny, R. A. (author)
  • Cregg, F. (author)
  • O'Dwyer, S. (author)
  • Walsh, C. (author)
  • Adams, J. (author)
  • Banzi, R. (author)
  • Breuilh, L. (author)
  • Daly, L. (author)
  • Hendrix, S. (author)
  • Aisen, P. (author)
  • Gaynor, S. (author)
  • Sheikhi, A. (author)
  • Taekema, D. G. (author)
  • Verhey, F. R. (author)
  • Nemni, R. (author)
  • Nobili, F. (author)
  • Franceschi, M. (author)
  • Zanetti, O. (author)
  • Konsta, A. (author)
  • Anastasios, O. (author)
  • Nenopoulou, S. (author)
  • Tsolaki-Tagarak, F. (author)
  • Pakaski, M. (author)
  • Dereeper, O. (author)
  • de la Sayette, V. (author)
  • Senechal, O. (author)
  • Lavenu, I. (author)
  • Devendeville, A. (author)
  • Calais, G. (author)
  • Crawford, F. (author)
  • Mullan, M. (author)
  • Aalten, P. (author)
  • Berglund, M. A. (author)
  • de Jong, D. L. K. (author)
  • Godefroy, O. (author)
  • Hutchinso, S. (author)
  • Loannou, A. (author)
  • Jonsson, Michael,1955Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry(Swepub:gu)xjonmi (author)
  • Kent, A. (author)
  • Kern, JürgenGothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry(Swepub:gu)xkerju (author)
  • Nemtsas, P. (author)
  • Panidou, M. K. (author)
  • Abdullah, L. (author)
  • Paris, D. (author)
  • van Spijker, G. J. (author)
  • Spiliotou, M. (author)
  • Thomoglou, G. (author)
  • Wallin, Anders,1950Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry(Swepub:gu)xwaand (author)
  • Frisoni, G. (author)
  • Nilvad Study, Grp (author)
  • Göteborgs universitetInstitutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi (creator_code:org_t)

Related titles

  • In:Journal of the American Heart Association: Ovid Technologies (Wolters Kluwer Health)8:102047-9980

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view